ENDRA Life Sciences Inc (NDRA)

ENDRA Life Sciences Inc. is a healthcare equipment and supplies company focused on developing technologies that enhance clinical diagnostic ultrasound. Its work centers on thermo-acoustic enhanced ultrasound, which uses a pulsed radio frequency energy source to send energy deep into tissue and generate ultrasonic waves for high-contrast imaging. The company says this technology is being developed for applications including non-alcoholic fatty liver disease, tissue composition assessment, temperature monitoring, vascular imaging, and tissue perfusion. Incorporated in 2007, ENDRA Life Sciences is based in Ann Arbor, Michigan. The listed security is common stock on NASDAQ under the symbol NDRA.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-NDRA
$6.95
11.6% Upside
Fair
$25
301.3% Upside
Bargain
Fair
0.0%
November 16, 2026
1.5x
9.344 M
8.153 M
4.3%
95.3%
-18.2
81.8%
Valuation • Fair Value

ENDRA Life Sciences Inc (NASDAQ-NDRA) Fair Value by Valuation Model

Review the available estimates for ENDRA Life Sciences Inc (NASDAQ-NDRA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$6.95

Estimated upside of 11.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$6.95

Comparable-company valuation reference.

Analyst Price Target

$25

Analysts imply upside of 301.3%.

How to read these valuation models

Use the 4 available valuation references for ENDRA Life Sciences Inc (NASDAQ-NDRA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for ENDRA Life Sciences Inc (NASDAQ-NDRA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-6.611 M

Current operating profitability reference.

EBITDA Forecast

103.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review ENDRA Life Sciences Inc (NASDAQ-NDRA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for ENDRA Life Sciences Inc (NASDAQ-NDRA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-18.2

Lower score that deserves closer risk review.

FCF / Net Income

81.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for ENDRA Life Sciences Inc (NASDAQ-NDRA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for ENDRA Life Sciences Inc (NASDAQ-NDRA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

55

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for ENDRA Life Sciences Inc (NASDAQ-NDRA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

ENDRA Life Sciences Inc (NASDAQ-NDRA) Stock Forecast & Technical Outlook

Review ENDRA Life Sciences Inc (NASDAQ-NDRA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for ENDRA Life Sciences Inc (NASDAQ-NDRA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for ENDRA Life Sciences Inc (NASDAQ-NDRA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for ENDRA Life Sciences Inc (NASDAQ-NDRA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for ENDRA Life Sciences Inc (NASDAQ-NDRA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for ENDRA Life Sciences Inc (NASDAQ-NDRA) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for ENDRA Life Sciences Inc (NASDAQ-NDRA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, ENDRA Life Sciences Inc (NASDAQ-NDRA) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ Fast Investor Answers

ENDRA Life Sciences Inc (NASDAQ-NDRA) Stock FAQ

Data-supported answers about ENDRA Life Sciences Inc (NASDAQ-NDRA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$6.95
Estimated upside 11.6%
Valuation Rating
Undervalued
Estimated upside of 11.6%
Analyst Target
$25
Implied upside 301.3%
Financial Health
Fair
Current financial-health read

The current fair value estimate for ENDRA Life Sciences Inc (NASDAQ-NDRA) is $6.95. This implies an estimated upside of 11.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 11.6% versus the current market price.

The available analyst price target for ENDRA Life Sciences Inc (NASDAQ-NDRA) is $25. The analyst target implies estimated upside of 301.3%.

The current financial health read for ENDRA Life Sciences Inc (NASDAQ-NDRA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for ENDRA Life Sciences Inc (NASDAQ-NDRA) is November 16, 2026.

The latest available data indicates no current dividend yield for ENDRA Life Sciences Inc (NASDAQ-NDRA).

The current market capitalization listed for ENDRA Life Sciences Inc is 9.344 M.

The current enterprise value listed for ENDRA Life Sciences Inc is 8.153 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for ENDRA Life Sciences Inc is NASDAQ-NDRA, and the stock is listed on NASDAQ.

ENDRA Life Sciences Inc (NASDAQ-NDRA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for ENDRA Life Sciences Inc is 4.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for ENDRA Life Sciences Inc is 95.3%. Free float helps investors understand how much of the share base is available for public trading.